ArticleScientific reports2026
Synergistic effects of platelet-rich plasma and teriparatide on osteoporotic fracture healing in OVX rats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To evaluate the combined efficacy of locally injected platelet-rich plasma (PRP) and systemically administered teriparatide (PTH) on fracture healing in osteoporotic rats. Thirty female Sprague-Dawley rats underwent ovariectomy (OVX) to induce osteoporosis, followed by a left femoral osteotomy with Kirschner wire fixation. Rats were randomized into five groups (n = 6 per group): Sham, Model (OVX + Fx), PRP (local injection of 0.3 mL autologous PRP biweekly), PTH (subcutaneous teriparatide 10 µg/kg/day), and Combination (PRP + PTH). Healing was assessed 6 weeks post-treatment via serum ELISA (measuring osteocalcin (OCN), platelet-derived growth factor (PDGF), transforming growth factor-beta 1 (TGF-β1)), radiography, biomechanical testing (ultimate load, stiffness), histology (H&E staining), and micro-computed tomography (BV/TV, Tb.Th, Tb.N, Tb.Sp). The Combination group exhibited significantly higher serum levels of OCN, PDGF, and TGF-β1 compared to the monotherapy groups (P < 0.05). Radiographic evaluation indicated nearly complete fracture bridging at 6 weeks in the Combination group, with superior mineralization density observed as early as 4 weeks. Biomechanically, the Combination group demonstrated the greatest increase in ultimate load (135.7%) compared to the Model group, surpassing the improvements seen with either PRP (90.5%) or PTH (78.6%) monotherapy. Micro-CT analysis confirmed the highest bone volume fraction (BV/TV) in the Combination group (0.337 ± 0.017), significantly greater than in the PRP (0.280 ± 0.012) and PTH (0.263 ± 0.015) groups. H&E staining revealed optimal trabecular continuity and minimal adipocyte infiltration in the Combination group. PRP (promoting local callus augmentation) and PTH (enhancing systemic mineralization) demonstrated complementary actions. Their combination synergistically restored bone microarchitecture and biomechanical strength in osteoporotic fractures, yielding outcomes superior to those achieved with monotherapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.